Latest Insider Transactions at Denali Therapeutics Inc. (DNLI)
This section provides a real-time view of insider transactions for Denali Therapeutics Inc. (DNLI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Denali Therapeutics Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Denali Therapeutics Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 02
2021
|
Peter S Klein Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,074
+28.02%
|
-
|
Jun 02
2021
|
Robert Nelsen Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,074
+14.3%
|
-
|
Jun 02
2021
|
Vicki L Sato Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,074
+1.5%
|
-
|
Jun 02
2021
|
David P Schenkein Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,074
+28.02%
|
-
|
Jun 02
2021
|
Marc Tessier Lavigne Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,074
+0.08%
|
-
|
Jun 01
2021
|
Ryan J. Watts President and CEO |
SELL
Open market or private sale
|
Indirect |
18,333
-0.21%
|
$1,136,646
$62.33 P/Share
|
Jun 01
2021
|
Douglas G. Cole Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,253
+50.0%
|
-
|
Jun 01
2021
|
Jennifer E. Cook Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,253
+50.0%
|
-
|
Jun 01
2021
|
Jay T Flatley Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
3,253
+0.98%
|
-
|
Jun 01
2021
|
Peter S Klein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,253
+50.0%
|
-
|
Jun 01
2021
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,253
+50.0%
|
-
|
Jun 01
2021
|
Robert Nelsen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,253
+23.9%
|
-
|
May 26
2021
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
1,666
-0.41%
|
$108,290
$65.83 P/Share
|
May 24
2021
|
Marc Tessier Lavigne Director |
SELL
Open market or private sale
|
Direct |
8,806
-0.35%
|
$528,360
$60.02 P/Share
|
May 21
2021
|
Marc Tessier Lavigne Director |
SELL
Open market or private sale
|
Direct |
37,957
-1.47%
|
$2,277,420
$60.13 P/Share
|
May 12
2021
|
Robert Nelsen Director |
BUY
Other acquisition or disposition
|
Direct |
2,537
+26.31%
|
-
|
May 12
2021
|
Robert Nelsen Director |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-4.92%
|
-
|
May 04
2021
|
Alexander O. Schuth COFO and Secretary |
SELL
Open market or private sale
|
Indirect |
10,000
-0.64%
|
$560,000
$56.13 P/Share
|
May 03
2021
|
Ryan J. Watts President and CEO |
SELL
Open market or private sale
|
Indirect |
18,333
-0.27%
|
$1,081,647
$59.16 P/Share
|
May 03
2021
|
Marc Tessier Lavigne Director |
SELL
Open market or private sale
|
Direct |
3,237
-0.06%
|
$194,220
$60.64 P/Share
|
Apr 28
2021
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
1,666
-0.41%
|
$101,626
$61.93 P/Share
|
Apr 05
2021
|
Alexander O. Schuth COFO and Secretary |
SELL
Open market or private sale
|
Indirect |
10,000
-0.63%
|
$560,000
$56.5 P/Share
|
Apr 01
2021
|
Ryan J. Watts President and CEO |
SELL
Open market or private sale
|
Indirect |
18,334
-0.27%
|
$1,026,704
$56.57 P/Share
|
Apr 01
2021
|
Marc Tessier Lavigne Director |
SELL
Open market or private sale
|
Direct |
50,000
-0.63%
|
$2,800,000
$56.7 P/Share
|
Mar 31
2021
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
1,666
-0.3%
|
$93,296
$56.21 P/Share
|
Mar 29
2021
|
Carole Ho Chief Medical Officer |
SELL
Open market or private sale
|
Indirect |
2,822
-1.71%
|
$152,388
$54.62 P/Share
|
Mar 22
2021
|
Robert Nelsen Director |
BUY
Other acquisition or disposition
|
Direct |
2,538
+35.72%
|
-
|
Mar 22
2021
|
Robert Nelsen Director |
SELL
Other acquisition or disposition
|
Indirect |
500,000
-4.69%
|
-
|
Mar 15
2021
|
Steve E. Krognes Director |
SELL
Open market or private sale
|
Indirect |
50,000
-1.41%
|
$3,100,000
$62.4 P/Share
|
Mar 09
2021
|
Ryan J. Watts President and CEO |
SELL
Bona fide gift
|
Indirect |
40,000
-1.73%
|
-
|
Mar 04
2021
|
Alexander O. Schuth COFO and Secretary |
SELL
Open market or private sale
|
Indirect |
10,000
-0.93%
|
$610,000
$61.24 P/Share
|
Mar 03
2021
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
1,666
-0.3%
|
$101,626
$61.89 P/Share
|
Mar 01
2021
|
Ryan J. Watts President and CEO |
SELL
Open market or private sale
|
Indirect |
18,334
-0.11%
|
$1,228,378
$67.62 P/Share
|
Mar 01
2021
|
Marc Tessier Lavigne Director |
SELL
Open market or private sale
|
Direct |
100,000
-0.53%
|
$6,700,000
$67.65 P/Share
|
Mar 01
2021
|
Carole Ho Chief Medical Officer |
SELL
Open market or private sale
|
Indirect |
7,092
-0.6%
|
$475,164
$67.93 P/Share
|
Feb 16
2021
|
Steve E. Krognes Director |
SELL
Open market or private sale
|
Indirect |
50,000
-1.34%
|
$3,250,000
$65.58 P/Share
|
Feb 12
2021
|
Douglas K Bratton > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,216,798
-18.17%
|
$144,091,870
$65.0 P/Share
|
Feb 11
2021
|
Ryan J. Watts President and CEO |
SELL
Open market or private sale
|
Indirect |
9,473
-0.2%
|
$663,110
$70.82 P/Share
|
Feb 11
2021
|
Steve E. Krognes Director |
SELL
Open market or private sale
|
Direct |
3,035
-1.51%
|
$212,450
$70.8 P/Share
|
Feb 11
2021
|
Alexander O. Schuth COFO and Secretary |
SELL
Open market or private sale
|
Indirect |
3,047
-0.28%
|
$213,290
$70.79 P/Share
|
Feb 11
2021
|
Carole Ho Chief Medical Officer |
SELL
Open market or private sale
|
Indirect |
3,156
-0.9%
|
$220,920
$70.83 P/Share
|
Feb 09
2021
|
Carole Ho Chief Medical Officer |
SELL
Open market or private sale
|
Indirect |
1,470
-0.29%
|
$110,250
$75.17 P/Share
|
Feb 09
2021
|
Steve E. Krognes Director |
SELL
Open market or private sale
|
Direct |
1,448
-5.13%
|
$107,152
$74.88 P/Share
|
Feb 09
2021
|
Alexander O. Schuth COFO and Secretary |
SELL
Open market or private sale
|
Indirect |
1,468
-0.14%
|
$110,100
$75.17 P/Share
|
Feb 09
2021
|
Ryan J. Watts President and CEO |
SELL
Open market or private sale
|
Indirect |
5,112
-0.07%
|
$378,288
$74.12 P/Share
|
Feb 08
2021
|
Ryan J. Watts President and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
14,316
+0.31%
|
-
|
Feb 07
2021
|
Carole Ho Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
4,250
+2.45%
|
-
|
Feb 07
2021
|
Steve E. Krognes Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,250
+22.76%
|
-
|
Feb 07
2021
|
Alexander O. Schuth COFO and Secretary |
BUY
Exercise of conversion of derivative security
|
Indirect |
4,250
+0.78%
|
-
|
Feb 04
2021
|
Alexander O. Schuth COFO and Secretary |
SELL
Open market or private sale
|
Indirect |
10,000
-0.62%
|
$670,000
$67.72 P/Share
|